CALC — CalciMedica, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$2.19
+$0.19 (+9.50%)
CalciMedica, Inc. Common Stock (CALC) is a biotechnology company listed on NASDAQ. It is led by A. Rachel Leheny Ph.D., based in 505 Coast Boulevard South, La Jolla, CA, United States, 92037, with about 15 employees. CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California.
Net income was -$18.8M. CALC currently screens at market cap $22.5M.
Use this CALC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CALC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CALC SEC filings page. Lician reads the product cache first so this HTML stays unique to CalciMedica, Inc. Common Stock even when a live quote feed is slow.
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California.
CALC Key Statistics
Market Cap
$22.49M
Volume
249,204
Previous Close
$0.57
Day Range
$0.55 – $0.60
EPS
-$1.22
Revenue
$0.00
Net Income
-$13.70M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
15
CALC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$13.70M | -$34.36M | -$7.82M | -$35.82M |
| EPS (Diluted) | -$1.22 | -$7.66 | -$111.16 | -$1.69 |
Total Assets
$19.79M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$7.93M
Operating Cash Flow
-$21.15M
Free Cash Flow
$0.00
CalciMedica, Inc. Common Stock Company Information
- CEO & Director
- A. Rachel Leheny Ph.D.
- Headquarters
- 505 Coast Boulevard South, La Jolla, CA, United States, 92037
- Website
- calcimedica.com
- Phone
- 858 952 5500
- IPO / Founded
- 2020-09-25
- Sector
- Healthcare
- Industry
- Biotechnology